SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: kidney
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; no BMI minimum stated; conditions: Obesity; Albuminuria
- Interventions
- Semaglutide; Placebo
- Conditions
- Obesity; Albuminuria
- Phase and size
- Phase 3 · 125 participants
- Dates
- Start 2022-03-14
Primary completion 2024-05-28 - Sponsor
- University Medical Center Groningen (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR)Week 1 to week 24
Published results in the collection
- Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART TrialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
02Eligibility
Who can take part
Inclusion Criteria: * Age ≥ 18 years * Body Mass index ≥ 27 kg/m2 * Albuminuria ≥ 30 mg/g and ≤ 3500 mg/g * eGFR ≥ 25 ml/min/1.73m2 * Stable renal function prior to entry into the study defined as no more than 30% eGFR change in 3 months prior to enrolment * Signed Informed Consent Exclusion Criteria: * Diagnosis with type 1 or type 2 Diabetes * Hba1c ≥ 6.5% at screening * Cardiovascular disease event in 3 months prior to enrollment * Treatment with GLP-1 RA \< 4 weeks prior to screening * Uncontrolled thyroid disease TSH\>6.0 mIU/L or \<0.4 mIU/L at screening * Acute pancreatitis \< 180 days prior to screening * History or presence of chronic pancreatitis * Females of child-bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures
03Change log
Registry changes
No changes recorded since the trial was added.